论文部分内容阅读
目的观察雷公藤多甙对老年糖尿病肾脏疾病患者蛋白尿水平改善的疗效和安全性。方法 45例2型糖尿病肾脏疾病患者随机分为治疗组(n=22)和对照组(n=23),对照组接受常规治疗,治疗组在常规治疗基础上加用雷公藤多甙一日30 mg,分3次口服,疗程6个月。期间定期复查患者的血常规、血糖、血压、24 h蛋白尿、血尿肌酐和肝功能等指标。结果两组治疗前后24 h蛋白尿定量明显下降,差异有统计学意义(P<0.01),且治疗后组间比较差异也有统计学意义(P<0.05),同时治疗过程中未见显著不良反应发生。结论雷公藤多甙治疗老年肾脏疾病患者蛋白尿的疗效肯定且安全。
Objective To observe the effect and safety of tripterygium glycosides on the improvement of proteinuria in elderly patients with diabetic nephropathy. Methods Forty-five patients with type 2 diabetic nephropathy were randomly divided into treatment group (n = 22) and control group (n = 23). The control group received routine treatment. The treatment group received tripterygium glycosides 30 mg, 3 times orally, course of treatment for 6 months. During the regular review of the patient’s blood, blood glucose, blood pressure, 24 h proteinuria, serum creatinine and liver function and other indicators. Results The proteinuria of 24 hours before and after treatment in both groups decreased significantly (P <0.01), and there was also significant difference between the two groups after treatment (P <0.05). No significant adverse reactions were found in the course of treatment occur. Conclusion The efficacy of triptolide in the treatment of proteinuria in elderly patients with renal disease is affirmative and safe.